MDMA-assisted therapy for PTSD to be reviewed by US FDA
American public benefit corporation (PBC) Lykos Therapeutics have announced that the US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting their new drug application (NDA) for MDMA capsules, which are to be used in combination with psychological interventions for the treatment of PTSD in adults.
Lykos Therapeutics, a California-based PBC, announced in a press release on May 6, 2024 that the US FDA will be investigating data in support of the company’s NDA for midomafetamine capsules, more commonly known as MDMA. Often used as a recreational drug, MDMA acts as a stimulant and a psychedelic. A synthetic chemical, MDMA affects how serotonin is used by neurons to communicate with each other. As a psychedelic, MDMA causes changes in perception and euphoric sensations for users. Investigational MDMA has been clinically studied for indications including PTSD but has never been approved by any regulatory agency.
The US FDA PDAC will review the results of several studies evaluating the efficacy and safety of MDMA when used in combination of psychotherapy and other mental health support services. Amy Emerson, CEO of Lykos Therapeutics, states, “This will be the first MDMA-assisted therapy and psychedelic-assisted therapy to be reviewed by the [PDAC], a significant milestone in the field of psychedelic medicine, resulting from decades of clinical research and advocacy. We look forward to the opportunity to discuss the comprehensive data package of investigational MDMA and how, if approved, it may be used as a prescription treatment in combination with psychological intervention in adults with PTSD.”
The FDA accepted the NDA for midomafetamine from Lykos Therapeutics in February 2024 for MDMA-assisted therapy of PTSD in adults. The NDA application was granted Priority Review. Drugs granted this review will, if approved, be classed with significant improvement in the safety or effectiveness of treatment, diagnosis, or prevention of serious conditions compared to standard applications. Should the midomafetamine capsules be approved, they will be the first drug product approved for MDMA-assisted therapy and psychedelic-assisted therapy.
Source:
Lykos Therapeutics Announces FDA Advisory Committee Meeting to Review Investigational MDMA-Assisted Therapy for PTSD [Accessed May 8, 2024] https://news.lykospbc.com/2024-05-06-Lykos-Therapeutics-Announces-FDA-Advisory-Committee-Meeting-to-Review-Investigational-MDMA-Assisted-Therapy-for-PTSD
Related News
-
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future. -
News Pharma giants battle over COVID-19 patents in London courts
Two key players in the COVID-19 vaccine story – Pfizer/BioNTech and Moderna – have begun the latest chapter of their global legal battle over patents concerning technology for the development of mRNA therapeutics such as the COVID-19 vaccin... -
News Women in Pharma: Diversi‘tea’ at CPHI North America
CPHI North America will unite the pharmaceutical supply chain in Philadelphia from May 7–9, 2024 for 3 days of innovation and connections. As part of the content Agenda, our Diversity Track will bring the industry together to discuss the imperati... -
News CPHI Online Webinar Series – Optimising Pharma Manufacturing through Digital Transformations
This month’s CPHI Webinar Series explored achieving manufacturing excellence in pharma through the digitalisation of daily processes. Presented by Joe Doyle, Head of Sales at EviView, and Bikash Chatterjee, President and Chief Scientific Off... -
News Western pharma groups warn of supply disruptions over China anti-spy law
China’s anti-espionage laws have caused concern among western pharmaceutical groups over potential arrests or denial of access for foreign inspectors in China-based facilities and manufacturing partners, posing a risk to the supply of drug produc... -
News More to celebrate at the CPHI Milan Pharma Awards 2024
The CPHI Milan Pharma Awards, which are now open for nominations until 18 May 2024, celebrate the innovators making a difference. This year, two new categories have been added to further honour the contributions of a diverse range of pharma professiona... -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News The 2024 Pharma Outsourcing Forecast: strategic partnerships across global landscapes
For the pharmaceutical industry, outsourcing drug development, manufacturing, and research operations to contract organisations is not just a passing trend – increasingly, the partnership between drug sponsor and drug vendor is one of vital impor...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance